Guidance for Reagents for Detection of Specific Novel Influenza A Viruses

ICR 201303-0910-002

OMB: 0910-0584

Federal Form Document

Forms and Documents
IC Document Collections
ICR Details
0910-0584 201303-0910-002
Historical Active 201001-0910-006
HHS/FDA 19128
Guidance for Reagents for Detection of Specific Novel Influenza A Viruses
Extension without change of a currently approved collection   No
Regular
Approved without change 04/23/2013
Retrieve Notice of Action (NOA) 03/20/2013
  Inventory as of this Action Requested Previously Approved
04/30/2016 36 Months From Approved 04/30/2013
20 0 20
300 0 300
0 0 0

OMB clearance is being sought for an information collection that has been established as a special control for the class II device type, Novel Influenza A Reagents. This classification results from the review of a request from a device sponsor (CDC) for a diagnostic test intended to diagnose influenza subtype H5 (Asian lineage), commonly known as avian flu. This classification permits the legal distribution of this device, and the information collection addressed here plays a significant role in providing a reasonable assurance of the safety and effectiveness of this device and of similar future devices. Specifically, the information collection asks sponsors to obtain and analyze data postmarket to ensure the continued reliability of the device, given the propensity of influenza viruses to mutate and the potential for changes in disease prevalence. This involves collecting data on the clinical performance of the device under new prevalence conditions if there is a change in prevalence of influenza caused by the specific novel virus that the device is intended to detect, as compared to the prevalence of this virus when the clinical studies described in the 510(k) were conducted.

US Code: 21 USC 360c Name of Law: Sec 513 Classification of Devices Intended for Human Use
  
None

Not associated with rulemaking

  77 FR 58997 09/25/2012
78 FR 15952 03/13/2013
No

1
IC Title Form No. Form Name
Guidance for Reagents for Detection of Specific Novel Influenza A Viruses

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 20 20 0 0 0 0
Annual Time Burden (Hours) 300 300 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$0
No
No
No
No
No
Uncollected
Daniel Gitteson 3017965156 daniel.gitteson@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/20/2013


© 2024 OMB.report | Privacy Policy